MitraGen will simplify mitral valve repair, allowing physicians to offer definitive treatment in a minimally invasive cardiac cath lab procedure, avoiding the need for open heart surgery.
Today patients suffering from mitral valve disease are faced with high risk open heart surgery as their only option. Less than 10% of patients diagnosed with mitral valve disease are offered surgery, leaving physicians to use medications, not to correct the problem but to try to manage the patient's symptoms.
MitraGen's "no hardware left behind" technology, will allow physicians to offer definitive mitral valve repair in a minimally invasive cardiac cath lab procedure avoiding the need for open heart surgery.